Literature DB >> 8464905

Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells.

M H Kraus1, P Fedi, V Starks, R Muraro, S A Aaronson.   

Abstract

The predicted human erbB-3 gene product is closely related to epidermal growth factor receptor (EGFR) and erbB-2, which have been implicated as oncogenes in model systems and human neoplasia. We expressed the erbB-3 coding sequence in NIH 3T3 fibroblasts and identified its product as a 180-kDa glycoprotein, gp180erbB-3. Tunicamycin and pulse-chase experiments revealed that the mature protein was processed by N-linked glycosylation of a 145-kDa erbB-3 core polypeptide. The intrinsic catalytic function of gp180erbB-3 was shown by its ability to autophosphorylate in vitro. Ligand-dependent signaling of its cytoplasmic domain was established employing transfectants that express a chimeric EGFR/erbB-3 protein, gp180EGFR/erbB-3. EGF induced tyrosine phosphorylation of the chimera and promoted soft agar colony formation of such transfectants. These findings combined with the detection of constitutive tyrosine phosphorylation of gp180erbB-3 in 4 of 12 human mammary tumor cell lines implicate the activated erbB-3 product in the pathogenesis of some human malignancies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8464905      PMCID: PMC46204          DOI: 10.1073/pnas.90.7.2900

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Construction and applications of a highly transmissible murine retrovirus shuttle vector.

Authors:  C L Cepko; B E Roberts; R C Mulligan
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

2.  Preparation of monoclonal antibodies: strategies and procedures.

Authors:  G Galfrè; C Milstein
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

3.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

4.  Human tumor cell lines with EGF receptor gene amplification in the absence of aberrant sized mRNAs.

Authors:  C R King; M H Kraus; L T Williams; G T Merlino; I H Pastan; S A Aaronson
Journal:  Nucleic Acids Res       Date:  1985-12-09       Impact factor: 16.971

5.  A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF.

Authors:  S Higashiyama; J A Abraham; J Miller; J C Fiddes; M Klagsbrun
Journal:  Science       Date:  1991-02-22       Impact factor: 47.728

6.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.

Authors:  J Downward; Y Yarden; E Mayes; G Scrace; N Totty; P Stockwell; A Ullrich; J Schlessinger; M D Waterfield
Journal:  Nature       Date:  1984 Feb 9-15       Impact factor: 49.962

7.  Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells.

Authors:  C R Lin; W S Chen; W Kruiger; L S Stolarsky; W Weber; R M Evans; I M Verma; G N Gill; M G Rosenfeld
Journal:  Science       Date:  1984-05-25       Impact factor: 47.728

Review 8.  Growth factors and cancer.

Authors:  S A Aaronson
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

9.  Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines.

Authors:  Y H Xu; N Richert; S Ito; G T Merlino; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

10.  Transforming growth factors produced by retrovirus-transformed rodent fibroblasts and human melanoma cells: amino acid sequence homology with epidermal growth factor.

Authors:  H Marquardt; M W Hunkapiller; L E Hood; D R Twardzik; J E De Larco; J R Stephenson; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

View more
  28 in total

1.  Positive and negative regulation of endogenous genes by designed transcription factors.

Authors:  R R Beerli; B Dreier; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

2.  Two chimeric receptors of epidermal growth factor receptor and c-Ros that differ in their transmembrane domains have opposite effects on cell growth.

Authors:  Q Xiong; J L Chan; C S Zong; L H Wang
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

3.  Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors.

Authors:  A Arcaro; M J Zvelebil; C Wallasch; A Ullrich; M D Waterfield; J Domin
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

4.  Identification of ErbB3-stimulated genes using modified representational difference analysis.

Authors:  C F Edman; S A Prigent; A Schipper; J R Feramisco
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

5.  ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation.

Authors:  Fumin Shi; Shannon E Telesco; Yingting Liu; Ravi Radhakrishnan; Mark A Lemmon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

6.  Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein.

Authors:  S L Sierke; K Cheng; H H Kim; J G Koland
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

Review 7.  The type I growth factor receptors in human breast cancer.

Authors:  T Rajkumar; W J Gullick
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

8.  Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.

Authors:  P M Guy; J V Platko; L C Cantley; R A Cerione; K L Carraway
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

Review 9.  Antiestrogen action and growth factor regulation.

Authors:  L C Murphy
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

10.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.